Form 4: Director Margaret Dugan Acquires BeOne Medicines Shares

Director Margaret Dugan was granted 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Summary

• Director Margaret Dugan acquired 18,980 ordinary shares in the form of restricted share units (RSUs).
• The transaction occurred on June 11, 2026.
• Following this transaction, the director's total beneficial ownership increased to 73,164 ordinary shares.
• The shares were acquired at a price of $0, consistent with standard equity-based director compensation grants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of market impact.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standardized compensation practice for independent non-executive directors.

Negatives

• None identified.

Risks

• Vesting of the RSUs is contingent upon continued service on the board of directors.
• Vesting may be subject to specific conditions outlined in the Company's Independent Non-Executive Director Compensation Policy.

Future Outlook

The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date or the date of the next annual general meeting, subject to continued board service.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard governance practice in the biotechnology sector to ensure long-term alignment between leadership and investors.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard corporate governance practices for publicly traded biotech firms.
• The vesting schedule tied to annual general meetings or one-year anniversaries is typical for independent director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive alignment of director interests with long-term company performance.

Next Steps

• Vesting of the 18,980 restricted share units on the earlier of the first anniversary or the next annual general meeting.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Director Compensation, Restricted Share Units